| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals, Inc. (ZNTL) has 11 insiders with recent SEC Form 4 filings, including 3 buys and 7 sells. ZNTL is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.51M | $57.62M | - | |
| 10% | 6.46M | $27.55M | - | |
| Dir | 338.8K | $1.44M | - | |
| Dir | 250.4K | $1.07M | - | |
| Dir | 207.2K | $883.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Eastland Julia Marie | CEO &President | Buy | 28,500 | $1.73 | $49,344.90 | New | -16.7% | +39.7% | |
| Jan 31, 2025 | Skvarka Jan | Director | Buy | 60,000 | $1.72 | $103,446.00 | +67.0% | -16.7% | +39.7% | |
| Jan 31, 2025 | Walker Luke Nathaniel | Director | Buy | 14,200 | $1.76 | $24,966.44 | +19.6% | -16.7% | +39.7% | |
| Jan 2, 2025 | Lackner Mark60 | Chief Scientific Officer | Sell | 4,411 | $3.12 | $13,762.32 | -2.3% | -54.8% | -54.3% | |
| Oct 4, 2024 | Vultaggio Vincent | Principal Accounting Officer | Sell | 1,603 | $3.18 | $5,097.54 | -4.5% | -11.0% | -52.2% | |
| May 31, 2024 | Gallagher Cam81 | President, Interim CFO | Sell | 9,597 | $11.98 | $114,972.06 | -1.5% | -72.6% | -89.8% | |
| May 9, 2024 | Hausman Diana | Chief Medical Officer | Sell | 3,356 | $12.62 | $42,352.72 | -0.9% | -73.8% | -90.2% | |
| Feb 12, 2024 | Epperly Melissa B,72 | Chief Financial Officer | Sell | 2,573 | $11.44 | $29,435.12 | -0.6% | +2.2% | -81.9% | |
| Feb 12, 2024 | Gallagher Cam81 | President | Sell | 1,173 | $11.44 | $13,419.12 | -0.2% | +2.2% | -81.9% | |
| Feb 2, 2024 | Lackner Mark60 | Chief Scientific Officer | Sell | 1,585 | $11.54 | $18,290.90 | -0.8% | -4.1% | -85.0% |